Hypoxia-inducible factor 1-alpha (HIF-1-alpha) (HIF-1-alpha)

Hypoxia-inducible factor 1-alpha (HIF-1-alpha) is a master transcriptional regulator that mediates the cellular response to low oxygen availability. Under normal oxygen levels, the protein is targeted for rapid proteasomal degradation by the von Hippel-Lindau (VHL) tumor suppressor protein following hydroxylation by prolyl hydroxylase domain (PHD) enzymes (UniProt Q16665). In hypoxic conditions, HIF-1-alpha stabilizes, translocates to the nucleus, and dimerizes with HIF-1-beta to activate genes responsible for angiogenesis, erythropoiesis, and anaerobic metabolism (StatPearls, PMID: 30241163). This pathway is a critical driver of tumor progression and metastasis in solid cancers, where it helps cells survive in poorly oxygenated environments. Conversely, in chronic kidney disease, the pathway is therapeutically activated using PHD inhibitors to stimulate endogenous erythropoietin production and treat anemia (PMID: 33503383). Therapeutic strategies targeting this pathway include both inhibitors for oncology and stabilizers for hematological and ischemic conditions.

Other names

HIF1AMOP1PASD8Hypoxia-inducible factor 1 subunit alphaBasic-helix-loop-helix-PAS protein MOP1HIF-1 signaling pathway

HIF-1-alpha signaling is modulated through two primary pharmacological approaches: stabilization and inhibition. HIF-PH inhibitors (stabilizers) work by inhibiting prolyl hydroxylase domain (PHD) enzymes, which prevents the oxygen-dependent degradation of HIF-1-alpha, allowing it to accumulate and activate the transcription of erythropoietin (EPO) and other genes involved in red blood cell production (PMID: 33503383). Conversely, HIF inhibitors in oncology aim to reduce the expression, stability, or transcriptional activity of HIF-1-alpha to disrupt tumor angiogenesis and metabolic adaptation to hypoxic microenvironments (PMID: 30241163).